Selected article for: "cryptic epitope and SARS CoV structure"
Author: M. Gordon Joyce; Rajeshwer S. Sankhala; Wei-Hung Chen; Misook Choe; Hongjun Bai; Agnes Hajduczki; Lianying Yan; Spencer L. Sterling; Caroline E. Peterson; Ethan C. Green; Clayton Smith; Natalia de Val; Mihret Amare; Paul Scott; Eric D. Laing; Christopher C. Broder; Morgane Rolland; Nelson L. Michael; Kayvon Modjarrad
Title: A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
  • Document date: 2020_3_17
    • ID: ebbzx8yr_15
    Snippet: In summary, our data represents the most detailed structural information for the SARS-CoV-2 RBD to date and the first structure of the SARS-CoV-2 in complex with a human antibody. The presence of "cryptic" but protective epitopes for influenza (Bangaru et al., 2019) , and Ebola viruses (West et al., 2018) , have been previously described. The identification of a novel "cryptic" epitope for betacoronaviruses including SARS-CoV, and SARS-CoV-2 high.....
    Document: In summary, our data represents the most detailed structural information for the SARS-CoV-2 RBD to date and the first structure of the SARS-CoV-2 in complex with a human antibody. The presence of "cryptic" but protective epitopes for influenza (Bangaru et al., 2019) , and Ebola viruses (West et al., 2018) , have been previously described. The identification of a novel "cryptic" epitope for betacoronaviruses including SARS-CoV, and SARS-CoV-2 highlight a novel viral vulnerability that can be harnessed in combination with ACE2 receptor site targeting monoclonal antibodies for vaccine and therapeutic countermeasure development.

    Search related documents:
    Co phrase search for related documents
    • countermeasure development and human antibody: 1
    • countermeasure development and monoclonal antibody: 1, 2
    • countermeasure development and structural information: 1
    • countermeasure development and therapeutic countermeasure development: 1
    • cryptic epitope and human antibody: 1, 2, 3, 4, 5
    • cryptic epitope and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7
    • cryptic epitope and receptor site: 1, 2
    • cryptic epitope and SARS complex: 1, 2
    • Ebola virus and human antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • Ebola virus and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • Ebola virus and receptor site: 1, 2, 3, 4, 5, 6
    • Ebola virus and SARS highlight: 1
    • human antibody and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human antibody and previously describe: 1, 2
    • human antibody and receptor site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • human antibody and SARS complex: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • human antibody and SARS highlight: 1, 2
    • human antibody and structural information: 1, 2
    • human antibody SARS complex and SARS complex: 1